Many lives have been adversely affected by the opioid epidemic sweeping the nation. For years, many opioid prescription drug manufacturers have engaged in deceptive marketing and advertising practices, which has included making egregious misrepresentations and grossly exaggerated claims to consumers, doctors and other drug prescribers. While some people are prescribed opioids for legitimate reasons, too often, opioids are over-prescribed for medically improper or unnecessary reasons and purposes.
Goldenberg Heller & Antognoli is committed to helping tackle the opioid epidemic, while also ensuring that opioid drug manufacturers and distributers are held accountable for putting profits over people. We work alongside a growing number of counties and municipalities to help finally put an end to the opioid epidemic.
Our Approach to Opioid Litigation
Many opioid prescription drug distributors have turned a blind eye to their duties under State and Federal laws to put systems into place for the purposes of identifying and preventing opioid drug diversion. This influx of opioids throughout the U.S. leads to a myriad of issues, including:
- Drug dependence
- Overdoses and death
- Excessive financial burdens for communities and tax payers
Federal research institutes, such as the National Institute on Drug Abuse (NIDA), have also linked heroin usage to opioid medications.
Free Opioid Litigation Consultation
We assist clients in Illinois, Missouri and across the country. We are ready to discuss your specific legal needs and options.
“Your knowledge, patience, and comfortable approach made this experience much easier for me.”
“Your firm is so professional. They make me feel like family more than anything else. Everyone is very kind and courteous. They go to no limits to get the job done.”
“I get answers to all my questions the day I call, that alone is wonderful. I am very happy to have Goldenberg Heller & Antognoli representing me.”
Notable Settlements & Verdicts
Obtained over $1 million in settlements for individuals injured by a pharmaceutical drug that increased the risk of cancer.